Skip to main content
. 2018 Aug 14;9:890. doi: 10.3389/fphar.2018.00890

Figure 8.

Figure 8

The different between NRTis plus LPV/r and RAL plus LPV/r in the change of grade 3 or 4 adverse events, serious events and adherence. Each risk ratio represents the effect of the second-line treatment in people with HIV with previous ART failure. (A) are desired for grade 3 or 4 adverse events and serious events, whereas (B) are desired for adherence. CI, credible interval; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; RAL, Raltegravir; LPV/r, Ritonavir-boosted lopinavir.